Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Adenoma, Islet Cell 1

Interventions

Specimen Handling 195Magnetic Resonance Spectroscopy 154pembrolizumab 152Carboplatin 115Biopsy 110Cyclophosphamide 100Cisplatin 88Paclitaxel 80Gemcitabine 72Bevacizumab 70fludarabine 61Nivolumab 60Radiotherapy 52Fluorouracil 52Capecitabine 49Dexamethasone 48Pemetrexed 46Rituximab 44Oxaliplatin 44Docetaxel 44Leucovorin 43atezolizumab 42Doxorubicin 42venetoclax 39durvalumab 39Standard of Care 34Prednisone 34Temozolomide 33Radiation 33Cetuximab 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × incomplete Freund's adjuvant × 30 days × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡